SpliceBio has made up a US $216m alliance with Spark Therapeutics
SpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2191 entries already.
Entries by Thomas Gabrielczyk
Antiverse and GlobalBio Inc. extend collaboration
Antiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development
SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Sotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.
World Health Summit opened in Berlin
On Sunday, the World Health Summit with more than 300 speakers officially kicked off in Berlin. The three day event focuses on climate change and health, pandemic prevention, and digital technologies.
Synerkine Pharma BV secures EUR 12.1m in Series A extension
Dutch Synerkine Pharma BV has closed a Seris A extension financincg at €12.1m to accelerate clinical development of its pain killer SK-01.
AI helps classifying brain tumours during surgery
A method to quickly classify central nervous system (CNS) tumours, combining rapid sequencing and deep-learned AI models, may enable molecular diagnosis in less than 90 minutes, Dutch researchers report.
Test TSKgel UP-SW UHPLC SEC columns risk-free
Try TSKgel UP-SW columns for SEC analysis of biomolecules risk-free for 30 days
Infrastructure makes the difference
A well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster Berlin-Brandenburg, these include numerous technology parks in the region. The parks offer optimal space including state of the art laboratories to start-up and grown-up companies.
Agomab Therapeutics NV raises US$100m in Series C financing
Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline.
AstronauTx closes £48m Series A financing
Alzheimer’s specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimer’s diseas